Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Capital Group Investment Management PTE. LTD.

Key Points

• Capital Group Investment Management PTE. LTD. cut its Regeneron position by 51.9% in the fourth quarter, selling 3,089 shares and leaving it with 2,867 shares valued at about $2.21 million.
• Regeneron reported better-than-expected quarterly results, with EPS of $9.47 and revenue of $3.61 billion, both above estimates and revenue up 19% year over year.
• The company has several catalysts and overhangs: it expanded its cancer partnership with CytomX, highlighted encouraging Lynozyfic trial data, and faces a shareholder investigation from Pomerantz LLP that could pressure sentiment.

Capital Group Investment Management PTE. LTD. lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 51.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,867 shares of the biopharmaceutical company's stock after selling 3,089 shares during the quarter. Capital Group Investment Management PTE. LTD.'s holdings in Regeneron Pharmaceuticals were worth $2,213,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC grew its position in Regeneron Pharmaceuticals by 5.4% during the fourth quarter. Los Angeles Capital Management LLC now owns 100,508 shares of the biopharmaceutical company's stock valued at $77,579,000 after buying an additional 5,173 shares during the period. Havemeyer Place LP acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $330,000. Ramirez Asset Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $39,000. Greykasell Wealth Strategies Inc. grew its position in shares of Regeneron Pharmaceuticals by 31.0% in the fourth quarter. Greykasell Wealth Strategies Inc. now owns 478 shares of the biopharmaceutical company's stock valued at $369,000 after purchasing an additional 113 shares during the period. Finally, MCF Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company's stock valued at $35,000 after purchasing an additional 15 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron expanded its cancer therapy partnership with CytomX Therapeutics, a deal that could generate up to $4 billion in potential milestones and broadens its bispecific oncology pipeline. REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
• Positive Sentiment: The company also reported highly favorable Lynozyfic trial results in light chain amyloidosis, which supports the view that Regeneron’s clinical pipeline may have additional upside. A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results
• Positive Sentiment: Regeneron said it will highlight new data from its metabolic disease, ophthalmology and rare disease programs at upcoming ADA and ENDO meetings, giving investors another near-term catalyst to watch. Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
• Neutral Sentiment: Parabilis Medicines, a Regeneron-partnered biotech, is pursuing an IPO to advance zolucatetide into Phase III, which could indirectly reflect on Regeneron’s partner network but does not directly change REGN’s fundamentals. Parabilis eyes $475m IPO to push lead asset into Phase III
• Negative Sentiment: An investor alert from Pomerantz LLP announced an investigation into claims on behalf of Regeneron shareholders, which may create some legal overhang and weigh on sentiment. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $635.45 on Friday. The company's 50-day moving average price is $706.93 and its 200-day moving average price is $742.16. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The company has a market cap of $67.18 billion, a P/E ratio of 15.48, a P/E/G ratio of 1.40 and a beta of 0.25. Regeneron Pharmaceuticals, Inc. has a twelve month low of $485.00 and a twelve month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping the consensus estimate of $8.91 by $0.56. The firm had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company's revenue for the quarter was up 19.0% on a year-over-year basis. During the same period last year, the firm posted $8.22 earnings per share. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were paid a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 9.16%.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Sanford C. Bernstein dropped their target price on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 8th. Guggenheim lifted their target price on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a "buy" rating in a research report on Friday, May 1st. Citigroup lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their target price for the company from $900.00 to $700.00 in a research report on Monday, May 18th. Royal Bank Of Canada dropped their target price on shares of Regeneron Pharmaceuticals from $762.00 to $707.00 and set a "sector perform" rating on the stock in a research report on Monday, May 18th. Finally, Piper Sandler dropped their target price on shares of Regeneron Pharmaceuticals from $875.00 to $855.00 and set an "overweight" rating on the stock in a research report on Monday, May 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $792.65.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the firm's stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director directly owned 17,503 shares of the company's stock, valued at approximately $12,343,815.72. This trade represents a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company's stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.